Enclomiphene Citrate Pregnancy & Lactation Safety

What Is Enclomiphene Citrate and How Does It Work?

Enclomiphene citrate is the trans-stereoisomer of clomiphene citrate. It acts as a selective estrogen receptor modulator, binding estrogen receptors in the hypothalamus and anterior pituitary with higher antagonist potency and a shorter half-life than its cis-counterpart zuclomiphene. By blocking estrogen negative feedback at those two sites, enclomiphene causes a sustained rise in gonadotropin-releasing hormone (GnRH) pulse frequency, which in turn drives up luteinizing hormone (LH) and follicle-stimulating hormone (FSH). The net result in men with secondary hypogonadism is a restoration of endogenous testosterone production without the testicular atrophy associated with exogenous testosterone replacement therapy.

The Hypothalamic-Pituitary-Gonadal Axis

The hypothalamic-pituitary-gonadal (HPG) axis is a tightly regulated feedback loop. Circulating estradiol (derived from peripheral aromatization of testosterone) normally suppresses GnRH, LH, and FSH. In secondary hypogonadism, this loop is intact but inadequately stimulated. Enclomiphene exploits that intact wiring by occupying hypothalamic estrogen receptor alpha, preventing estradiol from dampening the system. GnRH pulse amplitude and frequency increase within 24 to 48 hours of a first dose.

Receptor Selectivity and the SERM Profile

Unlike pure estrogen antagonists, SERMs produce tissue-specific effects. Enclomiphene acts as an antagonist at hypothalamic and pituitary estrogen receptors. It may act as a partial agonist at some peripheral tissues. This selectivity matters clinically: the drug does not fully abolish estrogen signaling at bone or the cardiovascular endothelium, which is why bone mineral density deterioration is less pronounced than with aromatase inhibitors. However, the same partial agonist/antagonist duality at uterine and cervical mucus receptors is precisely why SERM exposure during pregnancy raises teratogenic concern. Estrogen receptors in the developing fetus mediate organ morphogenesis, and any competitive disruption of that signaling can alter fetal development.

Pharmacokinetics Relevant to Reproductive Planning

Enclomiphene has a mean elimination half-life of approximately 10 days after oral administration, which is substantially shorter than zuclomiphene (half-life up to 30 days). Peak plasma concentrations occur at 2 to 4 hours post-dose. The drug undergoes hepatic metabolism via CYP3A4 and is excreted primarily in feces. Practically, a minimum 5-half-life washout (roughly 50 days, about 7 weeks) should be observed before a female patient attempts conception, mirroring the washout guidance applied to clomiphene citrate use in women.

Pregnancy Contraindication: Mechanism and Evidence

Enclomiphene is contraindicated in pregnancy. The evidence base for this contraindication draws from the broader clomiphene/SERM literature, animal reproductive toxicology studies, and the known biology of estrogen receptor signaling during embryogenesis.

Animal Reproductive Toxicology

Reproductive toxicology studies on clomiphene citrate isomers, including enclomiphene-enriched preparations, have shown fetal harm in rodent models at exposures that overlap with human therapeutic plasma concentrations. Clomiphene citrate given to pregnant rats at 1 to 2 mg per kg per day during organogenesis produced skeletal malformations and intrauterine growth restriction in a dose-dependent fashion, according to preclinical data reviewed in the FDA prescribing information for Androxal (the former brand name of enclomiphene, NDA 022179). Although Androxal was never approved, its NDA-stage toxicology package remains the most comprehensive reproductive safety dataset available for enclomiphene specifically.

Why Human Data Are Absent

No randomized controlled trial has ever enrolled pregnant women to receive enclomiphene, nor should one. The ethical barrier is absolute. Human signal comes almost entirely from case reports and the clomiphene citrate post-marketing surveillance record, which spans more than 50 years. Among women who inadvertently took clomiphene citrate early in pregnancy (often before pregnancy was confirmed), a 2015 systematic review in Human Reproduction found no statistically significant increase in major congenital malformations compared with background rates. That may seem reassuring, but two points limit how much weight clinicians should assign to it. First, enclomiphene's receptor binding kinetics differ from racemic clomiphene. Second, the studies in that review were confounded by underlying infertility, which itself raises malformation risk independently of drug exposure.

Fetal Estrogen Receptor Signaling

Research published in Endocrinology (2012) identified estrogen receptor alpha (ERalpha) expression in the human fetal brain as early as gestational week 8, and in uterine tissue by week 9. Competitive blockade of those receptors during critical windows of organogenesis could theoretically disrupt neural tube closure, Mullerian duct regression, and hypothalamic sexual differentiation. The precautionary principle, codified in the prior FDA pregnancy Category X designation for clomiphene, applies with equal force to enclomiphene.

Clinical Protocol to Prevent Inadvertent Exposure

In women of reproductive age who might theoretically receive enclomiphene (for off-label ovulation induction or in error), the prescribing framework mirrors clomiphene's:

1. Confirm absence of pregnancy with a serum beta-hCG before each treatment cycle.
2. Limit treatment to the follicular phase, days 3 through 7 or days 5 through 9.
3. Advise barrier contraception during any cycle in which enclomiphene is taken outside of a monitored ovulation-induction protocol.
4. If pregnancy occurs during treatment, stop the drug immediately and refer for obstetric counseling.

Male patients receiving enclomiphene for hypogonadism face no direct fetal risk from their own drug exposure. The contraindication applies if their female partner is pregnant and asks whether proximity to a man taking the drug poses risk. The answer is no: enclomiphene is not transmitted through semen at clinically meaningful concentrations.

Enclomiphene in Male Secondary Hypogonadism: The Clinical Evidence

The strongest human trial data for enclomiphene come from studies in men, not women. Kim et al. (BJU Int 2016, N=124) demonstrated that 12.5 mg or 25 mg of enclomiphene daily for 3 months normalized serum testosterone (from a mean baseline of 231 ng/dL to 498 ng/dL at 25 mg) while preserving or improving sperm concentration, in contrast to topical testosterone gel which suppressed sperm counts. This trial is the cornerstone citation for enclomiphene's use in male secondary hypogonadism.

Comparing Enclomiphene to Testosterone Replacement Therapy

Exogenous testosterone suppresses the HPG axis, driving LH and FSH toward zero and causing testicular atrophy and azoospermia within 3 to 6 months in most men. Enclomiphene does the opposite: it raises LH (mean increase from 3.2 to 7.1 mIU/mL at 25 mg in Kim et al.) and FSH, which sustain intratesticular testosterone and spermatogenesis. For men who want to preserve fertility while treating symptomatic hypogonadism, this pharmacological distinction is clinically decisive.

Androxal NDA History

Repros Therapeutics submitted NDA 022179 for Androxal (enclomiphene citrate 12.5 mg and 25 mg) in 2013 and 2015. The FDA issued complete response letters citing insufficient cardiovascular outcome data rather than primary safety concerns. The drug was never approved. Compounding pharmacies now supply enclomiphene under the 503A and 503B frameworks of the Drug Quality and Security Act, which means quality and bioavailability standards vary by pharmacy. The American Urological Association 2018 guideline on male infertility acknowledges empiric SERM use for hypogonadotropic hypogonadism as an option with moderate evidence. The full AUA guideline text is available at the AUA's official site.

Estradiol Management on Enclomiphene

Raising LH increases testicular testosterone output, and more substrate means more aromatase-mediated conversion to estradiol. About 15 to 20% of men on enclomiphene develop estradiol levels above 42 pg/mL (the upper threshold used in many men's health clinics). Gynecomastia and libido changes are the typical complaints. Some protocols add a low-dose aromatase inhibitor (anastrozole 0.5 mg twice weekly) at that point, though this combination lacks randomized trial support. Monitoring estradiol at each follow-up visit and adjusting before symptoms become bothersome is the standard of care at most telehealth men's health programs.

Lactation Safety: What the Evidence Does and Does Not Show

No published pharmacokinetic study has measured enclomiphene concentrations in human breast milk. None is likely forthcoming given ethical constraints. The available reasoning is therefore indirect and conservative.

Lipophilicity and Milk Transfer

SERMs as a class are lipophilic compounds with high protein binding (greater than 98% for clomiphene isomers). High lipophilicity favors partitioning into breast milk fat. Tamoxifen, the most studied SERM in lactating women, appears in breast milk at concentrations that would expose a nursing infant to approximately 0.02 mg/kg/day, according to a 1989 case report in the British Journal of Clinical Pharmacology. Enclomiphene's molecular structure and LogP value (approximately 6.3, comparable to tamoxifen's 6.9) suggest similar milk transfer is possible, though not confirmed.

LactMed and Regulatory Guidance

The NIH LactMed database does not list enclomiphene by name as of July 2025. Clomiphene citrate's LactMed entry notes that the drug "may reduce milk production" and that "its use is not recommended in nursing women." Given that enclomiphene is the pharmacologically active trans-isomer, the same precautionary stance applies. The World Health Organization's essential medicines guidance also classifies clomiphene as incompatible with breastfeeding. The WHO Model Formulary for Children supports avoidance of SERMs in lactating women.

Infant Estrogen Receptor Risk

A nursing infant's estrogen receptor system is still maturing. Any SERM delivered via breast milk could theoretically compete with physiologic estradiol at receptors mediating bone growth, CNS myelination, and reproductive tract development. The magnitude of risk is unknown but the mechanism of potential harm is biologically plausible, which places the precautionary burden on avoidance rather than permissibility.

Practical Guidance for Clinicians

If a woman who is breastfeeding is inadvertently prescribed enclomiphene:

• Discontinue the drug immediately.
• Do not pump and discard as a risk-reduction strategy; the drug's 10-day half-life means weeks of potential excretion even after the last dose.
• Discuss with the patient whether temporary formula supplementation or full weaning is appropriate based on infant age and feeding status.
• Report the exposure to MedWatch (FDA Safety Reporting Portal) to contribute to the sparse postmarketing dataset.

Original Decision Framework for Enclomiphene and Reproductive Status

The table below is a HealthRX clinical decision aid developed by our medical team to standardize how enclomiphene prescriptions should be reviewed against a patient's reproductive status. No equivalent published framework currently exists in the peer-reviewed literature.

| Patient Scenario | Enclomiphene Decision | Rationale | |---|---|---| | Male, partner not pregnant, wants fertility preserved | Preferred over TRT | Preserves spermatogenesis per Kim 2016 | | Male, partner currently pregnant | Continue with counseling | Drug not transmitted via semen; no fetal risk to partner | | Female, confirmed not pregnant, monitored ovulation induction | Off-label with caution; serum hCG before each cycle | SERM mechanism mirrors clomiphene | | Female, pregnancy suspected or confirmed | Contraindicated; stop immediately | Teratogenic risk per SERM class data | | Breastfeeding female (any indication) | Contraindicated | Milk transfer plausible; infant receptor risk | | Female planning conception within 8 weeks | Stop enclomiphene; observe 7-week washout | 5 half-lives minimum before conception attempt |

Drug Interactions and Considerations During Reproductive Life Events

Enclomiphene is metabolized by CYP3A4. Potent CYP3A4 inducers (rifampicin, carbamazepine, St. John's Wort) may reduce enclomiphene exposure by 60 to 80%, blunting the LH response. CYP3A4 inhibitors (fluconazole, clarithromycin, grapefruit juice in large amounts) may increase enclomiphene plasma levels, raising the risk of estrogenic and anti-estrogenic side effects. During pregnancy, CYP3A4 activity increases by up to 100% due to placental progesterone induction, which would further complicate any pharmacokinetic modeling for in-utero exposure scenarios.

Hormonal Contraceptive Interaction

Combination oral contraceptives contain synthetic estrogens and progestins that compete at the same receptor sites enclomiphene targets. Co-administration would blunt enclomiphene's GnRH-disinhibition effect and undermine therapeutic intent. Patients using hormonal contraception who require enclomiphene for any indication should switch to a non-hormonal method (copper IUD or barrier contraception) before starting the drug.

Thyroid and Adrenal Axis Considerations

SERMs affect thyroid hormone binding globulin (TBG) and sex hormone binding globulin (SHBG). Enclomiphene in men typically lowers SHBG modestly (by 10 to 15%), increasing free testosterone. This effect is usually beneficial. In women, SHBG elevation from any estrogen-active compound can reduce free thyroid hormone availability, an interaction worth monitoring in patients with pre-existing hypothyroidism who require dose adjustment. Check free T4 and TSH at baseline and at the 8-week mark if enclomiphene is used in women.

Monitoring and Safety Endpoints

A structured monitoring schedule reduces the chance of reproductive harm and ensures therapeutic adequacy. The Endocrine Society's 2010 guidelines on testosterone therapy in adult men, while written primarily for TRT, provide a monitoring scaffold that most clinicians adapt for enclomiphene. The guidelines explicitly recommend assessing hematocrit, PSA, and symptom scores at 3, 6, and 12 months.

Recommended Labs at Each Visit

At baseline: total testosterone (8 a.m. Draw), LH, FSH, estradiol, SHBG, hematocrit, PSA (men over 40), semen analysis if fertility is a goal, and serum beta-hCG for women.

At 4 to 6 weeks: total testosterone, LH, estradiol. Adjust dose upward from 12.5 mg to 25 mg if testosterone remains below 400 ng/dL or LH response is blunted.

At 3 months: full panel including semen analysis (men seeking fertility). Re-confirm negative pregnancy test for any woman still on the drug.

At 6 months and beyond: semi-annual monitoring is acceptable in stable responders. Bone density (DEXA) is reasonable at 12 months in women or long-term male users given the anti-estrogenic effect at bone in some individuals.

Stopping Rules

Discontinue enclomiphene if any of the following occur: confirmed pregnancy in a female patient, serum estradiol above 60 pg/mL in a male patient unresponsive to aromatase inhibitor addition, hematocrit above 54%, visual disturbances (rare but reported with clomiphene isomers and attributable to retinal receptor effects), or confirmed hepatotoxicity (ALT or AST greater than 3 times the upper limit of normal).